Neurocrine’s Ingrezza capsule approved to treat Tardive dyskinesia

Neurocrine Biosciences’ Ingrezza (valbenazine) capsules has been approved by US FDA (food and Drug Administration) for treatment of tardive dyskinesia (TD).

TD is characterised by uncontrollable, abnormal and repetitive movements of the trunk, extremities and / or face and is caused by treatments such as antipsychotics and other medications that block dopamine receptors in the brain. Its symptoms can be severe and are often persistent and irreversible.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor and clinical studies have shown that it provides rapid improvement in TD signs and symptoms.

In nearly 20 trials done on 1,000 individual, No worsening in safety scale scores for depression, suicidal ideation or behaviours was observed.

Neurocrine Biosciences CEO Kevin Gorman said: that the approval of Ingrezza represents a turning point for these patients and their care partners, offering a meaningful treatment where before there was little hope.

“Neurocrine would like to thank the many clinical investigators and TD patients who participated in our clinical trials.”